Nat. Immunol. 17, 1291–1299 (2016); published online 12 September 2016; corrected after print 19 October 2016

In the version of this article initially published, author Mikael Ebbo was missing from the author list. The correct list is as follows: Frédéric Vély1,2,20, Vincent Barlogis3,20, Blandine Vallentin3,20, Bénédicte Neven4–7,20, Christelle Piperoglou1,2, Mikael Ebbo1,8, Thibaut Perchet9,10, Maxime Petit9,10, Nadia Yessaad11, Fabien Touzot5,12, Julie Bruneau5,13, Nizar Mahlaoui47, Nicolas Zucchini14, Catherine Farnarier2, Gérard Michel3, Despina Moshous47, Stéphane Blanche47, Arnaud Dujardin15, Hergen Spits16, Jörg H W Distler17, Andreas Ramming17, Capucine Picard4–7,18, Rachel Golub9,10, Alain Fischer4–7,19,21 & Eric Vivier1,2,21. The correct affiliation list ends as follows: 8APHM, Hôpital de la Timone, Service de Médecine Interne, Marseille, France. 9Institut Pasteur, Unité de Lymphopoièse, INSERM, Paris, France. 10Université Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, France. 11MI-mAbs consortium, Aix-Marseille University, Marseille, France. 12APHP, Hôpital Necker-Enfants Malades, Biotherapy Unit, Paris, France. 13APHP, Hôpital Necker-Enfants Malades, Service d'anatomopathologie, Paris, France. 14BD Biosciences, Le Pont-de-Claix, France. 15Innate-Pharma, Marseille, France. 16Academic Medical Center at the University of Amsterdam, Arizona Amsterdam, the Netherlands. 17Department of Internal Medicine, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. 18APHP, Hôpital Necker-Enfants Malades, Study Center of Immunodeficiencies, Paris, France. 19College de France, Paris, France. 20These authors contributed equally to this work. 21These authors jointly directed this work. The correct Author Contributions section ends as follows: “...and M.E., N.M., N.Z., C.F., G. M., D.M., S.B., A.D., H.S. and C. Pic. provided key expertise, reagents or samples.”

In addition, the description of patient C9 was incorrect in the text and legend for Figure 4b,d. The correct text (in the final paragraph of the fourth subsection of Results) is as follows: “In addition, NKp46+ ILCs and ILC2s were readily observed in tissues from patients treated with myeloablative HSCT, as illustrated by the analysis of skin biopsies from a patient with SCID who had mutation of RAG2 (C10) and was treated with myeloablative HSCT (Fig. 4b,d).... As a control, tissue-resident gut ILCs were observed in a patient with SCID who had mutation of RAG1 (C9) but was treated with 'pheno-related' HSCT (related donor with more than one compatible HLA haplotype but not genetically identical) under non-myeloablative conditions (Fig. 4b,d). The correct Figure 4b,d legend is as follows: “(b) Microscopy of tissue sections from patients who were treated with HSCT (stained as in a): duodenum (left) or colon (right) from C9 (RAG1 mutation) and skin from C10 (RAG2 mutation) (middle), at 15 months (C9) or 4 months (C10) after HSCT....(d) Microscopy of tissue sections from patients with SCID (colon from P5 and skin from P11 (as in a); colon from C9 and skin from C10 (as in b))....”

Also, a label was missing under Figure 1d, far left; that should be labelled as 'LinCD127+'.

Finally, the description of lung NK cells in the final paragraph of Results was incorrect; that text should read as follows: “Similarly, lung NK cells (LinNKp46+NK1.1+CD127) underwent reconstitution....” These errors have been corrected in the PDF and HTML versions of this article.